MWN109 (including injection and oral tablets) is a drug independently developed by the company
December 17, 2025
Source: drugdu
28
Securities Daily Online News: On December 16, Lepu Medical stated in response to investor inquiries on its interactive platform that MWN109 (including injection and oral tablets) is a drug independently developed by the company. The company holds its global intellectual property rights and has already applied for patent protection for key aspects, such as the core compound structure. Furthermore, the drug has passed the Freedom to Operate (FTO) analysis.
https://finance.eastmoney.com/a/202512163593263249.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Subsidiary Signs Exclusive Licensing Agreement for GenSci098 Injection Project December 17, 2025
- Kangfeng Biotechnology’s Anti-Gastroesophageal Reflux System Receives Approval from the Drug Administration December 17, 2025
- Cell Metabolism | Efficacy of Akkermansia muciniphila Supplementation in Overweight/Obese Patients with Type 2 Diabetes December 17, 2025
- Major Breakthrough! China’s First Injectable Silk Fibroin Gel Enters Clinical Trials December 17, 2025
- Can AOC become the “next stop” for oligonucleotide therapy? December 17, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
